Get the latest news, insights, and market updates on CGON (CG Oncology, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim
CG Oncology, Inc. (NASDAQ:CGON) is one of the best healthcare stocks with the highest upside. On October 7, CG Oncology, Inc. (NASDAQ:CGON) was initiated with a Buy rating by Guggenheim analyst Brad Canino, who assigned the stock a $90 price target. The firm told investors in a research note that it sees the company “rising […] Oct 18, 2025 - $CGON
CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results
CG Oncology (CGON) is in the spotlight after several analysts, including Guggenheim, initiated coverage. This attention is supported by promising late-stage trial results for its lead bladder cancer therapy and anticipation of an FDA review next year. See our latest analysis for CG Oncology. Momentum has been strongly building for CG Oncology, as the stock has climbed over 66% in the past 90 days, capped by an 11.55% one-week share price return following analyst bullishness and positive... Oct 10, 2025 - $CGON
CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment
CG Oncology Inc. (NASDAQ:CGON) is one of the best new stocks to buy right now. On September 17, Morgan Stanley raised the firm’s price target on CG Oncology to $79 from $56, while maintaining an Overweight rating on the shares. Earlier in August, CG Oncology announced significant clinical advancements in its bladder cancer pipeline and […] Sep 22, 2025 - $CGON
CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last?
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Sep 18, 2025 - $CGON
CG Oncology (CGON) Reports Promising Results In BOND-003 Trial
CG Oncology (CGON) recently reported promising developments from the BOND-003 trial with their investigational therapy, cretostimogene, showing significant efficacy in non-muscle invasive bladder cancer patients. Alongside this, the completion of enrollment in the PIVOT-006 study marks a strategic advancement in their clinical program. These events likely supported the company’s share price increase of 35% over the past month. Broad market moves, including record highs in the S&P 500 and... Sep 10, 2025 - $CGON
CG Oncology (CGON) Is Up 23.3% After 24-Month Complete Response Data in Phase 3 Bladder Cancer Study
CG Oncology recently released updated data from its Phase 3 BOND-003 Cohort C study, which showed a 41.8% 24-month complete response rate for cretostimogene monotherapy in heavily pretreated patients with high-risk non-muscle invasive bladder cancer. The results highlight that if a patient responds to therapy at 12 months, there is a 90% likelihood they will maintain a complete response at 24 months, an unprecedented outcome for this patient population. We’ll explore how these positive... Sep 8, 2025 - $CGON
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month responders remained disease free at 24 Months -- Safety profile remains consistent - IRVINE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commerc Sep 5, 2025 - $CGON
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple